Product Description
Nihon is developing NPO-13 as a treatment for patients with moderate to severe Colonic Spasm during Colonoscopy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04097574)
Mechanisms of Action: Imaging Agent
Novel Mechanism: No
Modality: Diagnostic Agent
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Nihon Pharmaceutical Co., Ltd
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Spasm|Intestinal Diseases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT04097574 |
NPO-13-01/ED-01 | P2 |
Completed |
Intestinal Diseases |
2020-03-26 |
2020-08-19 |
||
NCT02265939 |
NPO-13 | P2 |
Completed |
Spasm |
2015-03-01 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|